Severe Compression Neuropathy Following Sudden Onset of Parkinsonian Immobility
Arch Neurol 42:720, Kurlan,R.,et al, 1985
Neurologic Complications of Heroin Addiction
Bull NY Acad Sci 49:4, Ritcher,R.W.,et al, 1973
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?
AJNR 38:1737-1741, Shams, S.,et al, 2017
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Exploring the Association Between Rosacea and Parkinson Disease
JAMA Neurol 73:529-534, Egeberg, A.,et al, 2016
Parkinsonism in a Diabetic Uremic Patient
Neurol 86:e225-e227, Osaki, Y.,et al, 2016
Clinical, Genetic, and Radiological Features of Extrapyramidal Movement Disorders in Mitochondrial Disease
JAMA Neurol 73:668-674, Martikainen, M.H.,et al, 2016
Cystic Lesions as a Rare Complication of Deep Brain Stimulation
Mov Disord Clin Pract 3:87-90, Sharma, V.D.,et al, 2016
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of DIagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality
AJNR 36:2010-2016, Noh, Y.,et al, 2015
Role of Brain Imaging in Early Parkinsonism
BMJ 324:d638, Breen,D.P.,et al, 2011
Association of Olfactory Bulb Volume and Olfactory Sulcus Depth with Olfactory Function in Patients with Parkinson Disease
AJNR 32:677-81, Wang, J.,et al, 2011
High-Resolution Diffusion Tensor Imaging in the Substantia Nigra of De Novo Parkinson Disease
Neurol 72:1378-1384,1374, Vaillancourt,D.E.,et al, 2009
Functional Imaging of the Cerebral Olfactory System in Patients with Parkinsons Disease
JNNP 79:19-24, Westermann,B.,et al, 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Neuroimaging of Bilateral Caudate Infarction Manifesting as Parkinsonian Gait Disorder
Conn Med 71:149-150, Finelli,P.F., et al, 2007
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Hemiparkinsonism-hemiatrophy Syndrome
Neurol 69:1585-1594, Wijemanne,S. &Jankovic,J., 2007
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Neurologic Manifestations in Welders with Pallidal MRI T1 Hyperintensity
Neurol 64:2033-2039,2001, Josephs,K.A.,et al, 2005
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Post-Stroke Movement Disorders; Report of 56 Patients
JNNP 75:1568-1574, Alarcon,F.,et al, 2004
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Pract Neurology 4:50-55, Razvi,S.S.M. &Muir,K.W., 2004
Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases
Arch Neurol 60:337-341, 320, Zarow,C.,et al, 2003
Randomized Trial of Pallidotomy Versus Medical Therapy for Parkinson's Disease
Ann Neurol 53:558-569, Vitek,J.L.,et al, 2003
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Disappearance of Resting Tremor After "Stereotaxic" Thalamic Stroke
Neurol 61:1014-1015, Probst-Cousin,S.,et al, 2003
Diffusion-weighted MRI Differentiates the Parkinson Variant of Multiple System Atrophy from PD
Neurol 58:575-580, Schocke,M.F.H.,et al, 2002
T2-weighted MRI Differentiates Multiple System Atrophy from Parkinson's Disease
Neurol 59;1265-1267, Kraft,E.,et al, 2002
MR Imaging Findings After Stereotactic Radiosurgery Using the Gamma Knife
AJR 176:1589-1595, Friedman,D.P.,et al, 2001
Effects of Bilateral Posteroventral Pallidotomy on Gait of Subjects with Parkinson Disease
Arch Neurol 57:198-204, Siegel,K.L.&Metman,L.V., 2000
The Nonmotor Problems of Parkinson's Disease
The Neurologist 6:18-27, Friedman,J.H.&Fernandez,H.H., 2000
Long-Term Follow-Up of Unilateral Pallidotomy in Advanced Parkinson's Disease
NEJM 342:1708-1714, Fine,J.,et al, 2000
Structural Changes of the Substantia Nigra in Parkinson's Disease as Revealed by MR Imaging
AJNR 21:697-701, Hutchinson,M.&Raff,U., 2000
Surgery for Parkinson Disease
Arch Neurol 57:1118-1125, Lang,A.E., 2000
Magnetic Resonance Imaging-Based Volumetry Differentiates Idiopathic Parkinson's Syndrome from Multiple System Atrophy and Progressive Supranuclear Palsy
Ann Neurol 45:65-74, Schulz,J.B.,et al, 1999
Clinical Correlates of Vascular Parkinsonism
Arch Neurol 56:98-102, Winikates,J.&Jancovic,J., 1999
Stereotactic Radiosurgical Pallidotomy and Thalamotomy with the Gamma Knife:MR Imaging Findings with Clinical Correlation-Preliminary Experience
Radiology 212:143-150, Friedman,D.P.,et al, 1999
Stereotactic Pallidotomy in the Treatment of Parkinson Disease,An Expert Opinion
Arch Neurol 56:1064-1069, Bronstein,J.M.,et al, 1999
Progress in Functional Neurosurgery for Parkinson's Disease
Lancet 354:1658-1659,1665, Quinn,N., 1999
Unilateral Pallidotomy for Parkinson's Disease:Results after More Than 1 Year
JNNP 67:511-517, Schrag,A.,et al, 1999
Evaluation of Surgery for Parkinson's Disease, A Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 53:1910-1921, Hallett,M.,et al, 1999